Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Manaf Alqahtani, Nitya Kumar, Dhuha Aljawder, Abdulkarim Abdulrahman, Mohammed Wael Mohamed, Fatema Alnashaba, Mohammed Abu Fayyad, Faisal Alshaikh, Fatima Alsahaf, Sawsan Saeed, Amal Almahroos, Zainab Abdulrahim, Sameer Otoom, Stephen L Atkin
Scientific Reports, doi:10.1038/s41598-022-08794-w
Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open-labelled randomized clinical trial. The trial was registered with Bahrain National Taskforce for Combatting COVID-19 on the 7th of May 2020 (registration code: NCT04387760). 150 symptomatic patients with COVID-19 disease were randomized into one of three arms: favipiravir, hydroxychloroquine, or standard care only. The primary outcome was the clinical scale at the end of study follow up (day 14 or on discharge/death) based on a points scale. The secondary outcomes were viral clearance, biochemical parameter changes and mortality at 30-days. Baseline characteristics did not differ between groups. The proportion of patients who achieved a clinical scale < 2 did not differ between groups. The favipiravir-treated and hydroxychloroquine-treated group showed increased viral clearance (OR, 95%CI 2.38, 0.83-6.78, OR, 95%CI 2.15, 0.78-5.92, respectively) compared to standard care, but this was not significant. The biochemical profile did not differ between groups, except for the platelet count (P < 0.03) and uric acid (P < 0.004) that were higher with favipiravir-treatment. Primary or secondary outcome measures did not differ between favipiravir, hydroxychloroquine, and standard therapy for mild to moderate COVID-19 disease; therefore, whilst favipiravir therapy appeared safe with a trend to increased viral clearance, there was no superior therapeutic utility. Clinical trials registration. NCT04387760. Registration date: 07/05/2020.
Coronavirus disease 2019 (COVID-19 ) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has developed into a pandemic with serious global public health and economic sequelae. As of May 30th, 2021, more than 170,695,962 million cases have been confirmed worldwide, leading to over 3,550,234 deaths 1 . Several vaccines have been shown to prevent or ameliorate COVID-19 disease, and several are currently developing 2 . However, for those that establish COVID-19 disease, there is a need for effective therapeutic agents to prevent the progressive deterioration that may be seen. There have been several reports of medications, such as remdesivir, with antiviral properties that have shown efficacy with shorter time-to-recovery against SARS-CoV-2 3 . It has been suggested that corticosteroids should be used cautiously unless there is evidence of refractory septic shock, acute respiratory distress syndrome (ARDS), or another compelling indication for their Use 4 . Hydroxychloroquine was thought to show great promise at the time that this study was initiated 5 but, in a large observational study, showed no differences in rates of intubation or death 6 , and a randomized trial..
Author contributions N.K.: data analysis, interpretation and preparation of the manuscript; D.A., A.A., F.A., M.A.F., F.A., F.A., S.S., A.A., Z.A., S.O. & S.A.: conception and design, data collection, manuscript review; S.S., N.K. & S.L.A.: writing and manuscript review; M.A.Q.: conception and design of the study and manuscript review.
Competing interests The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-08794-w. Correspondence and requests for materials should be addressed to M.A. Reprints and permissions information is available at www.nature.com/reprints. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Alqahtani, Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease, Sci. Rep,
doi:10.1038/s41598-021-89444-5Birkett, Day, Internal pilot studies for estimating sample size, Stat. Med
Diastolic, None, median (IQR)
Gautret, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med. Infect. Dis,
doi:10.1016/j.tmaid.2020.101663Gautret, Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105949Geleris, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med
Geleris, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2012410Ghazy, A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment, Sci. Rep
Hassanipour, The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Sci. Rep
Mehrotra, Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials, Ann. Intern. Med,
doi:10.7326/m20-6169Mehta, Mazer-Amirshahi, Alkindi, Pourmand, Pharmacotherapy in COVID-19; A narrative review for emergency providers, Am. J. Emerg. Med,
doi:10.1016/j.ajem.2020.04.035Mishima, Anzai, Miyazaki, Abe, Uric acid elevation by favipiravir, an antiviral drug, Tohoku J. Exp. Med,
doi:10.1620/tjem.251.87Mitjà, A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2021801Murohashi, Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases, Respir. Investig,
doi:10.1016/j.resinv.2020.08.001Néant, Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.2017962118Rao, Manissero, Steele, Pareja, A systematic review of the clinical utility of cycle threshold values in the context of COVID-19, Infect. Dis. Ther,
doi:10.1007/s40121-020-00324-3Shah, Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study), Int. Immunopharmacol,
doi:10.1016/j.intimp.2020.107301Sreekanth, Lai, Tackling COVID-19 using remdesivir and favipiravir as therapeutic options, Chembiochem Eur. J. Chem. Biol,
doi:10.1002/cbic.202000595Systolic, None, median (IQR
Tang, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Udwadia, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis
Vincent, Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine, Crit. Care Med,
doi:10.1097/00003246-199811000-00016Yao, Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis,
doi:10.1093/cid/ciaa237{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T04:36:24Z', 'timestamp': 1711600584424},
'reference-count': 31,
'publisher': 'Springer Science and Business Media LLC',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2022, 3, 23]],
'date-time': '2022-03-23T00:00:00Z',
'timestamp': 1647993600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'},
{ 'start': { 'date-parts': [[2022, 3, 23]],
'date-time': '2022-03-23T00:00:00Z',
'timestamp': 1647993600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title><jats:p>Favipiravir has antiviral activity against '
'influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of '
'this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care '
'(no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an '
'open-labelled randomized clinical trial. The trial was registered with Bahrain National '
'Taskforce for Combatting COVID-19 on the 7th of May 2020 (registration code: NCT04387760). '
'150 symptomatic patients with COVID-19 disease were randomized into one of three arms: '
'favipiravir, hydroxychloroquine, or standard care only. The primary outcome was the clinical '
'scale at the end of study follow up (day 14 or on discharge/death) based on a points scale. '
'The secondary outcomes were viral clearance, biochemical parameter changes and mortality at '
'30-days. Baseline characteristics did not differ between groups. The proportion of patients '
'who achieved a clinical scale\u2009<\u20092 did not differ between groups. The '
'favipiravir-treated and hydroxychloroquine-treated group showed increased viral clearance '
'(OR, 95%CI 2.38, 0.83–6.78, OR, 95%CI 2.15, 0.78–5.92, respectively) compared to standard '
'care, but this was not significant. The biochemical profile did not differ between groups, '
'except for the platelet count (<jats:italic>P</jats:italic>\u2009<\u20090.03) and uric '
'acid (<jats:italic>P</jats:italic>\u2009<\u20090.004) that were higher with '
'favipiravir-treatment. Primary or secondary outcome measures did not differ between '
'favipiravir, hydroxychloroquine, and standard therapy for mild to moderate COVID-19 disease; '
'therefore, whilst favipiravir therapy appeared safe with a trend to increased viral '
'clearance, there was no superior therapeutic utility.</jats:p><jats:p>Clinical trials '
'registration. NCT04387760. Registration date: 07/05/2020.</jats:p>',
'DOI': '10.1038/s41598-022-08794-w',
'type': 'journal-article',
'created': {'date-parts': [[2022, 3, 23]], 'date-time': '2022-03-23T11:04:41Z', 'timestamp': 1648033481000},
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 20,
'title': 'Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients '
'with mild/moderate COVID-19 disease',
'prefix': '10.1038',
'volume': '12',
'clinical-trial-number': [ { 'clinical-trial-number': 'nct04387760',
'registry': '10.18810/clinical-trials-gov'}],
'author': [ {'given': 'Manaf', 'family': 'AlQahtani', 'sequence': 'first', 'affiliation': []},
{'given': 'Nitya', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dhuha', 'family': 'Aljawder', 'sequence': 'additional', 'affiliation': []},
{'given': 'Abdulkarim', 'family': 'Abdulrahman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohammed Wael', 'family': 'Mohamed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fatema', 'family': 'Alnashaba', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohammed Abu', 'family': 'Fayyad', 'sequence': 'additional', 'affiliation': []},
{'given': 'Faisal', 'family': 'Alshaikh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fatima', 'family': 'Alsahaf', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sawsan', 'family': 'Saeed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Amal', 'family': 'Almahroos', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zainab', 'family': 'Abdulrahim', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sameer', 'family': 'Otoom', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephen L.', 'family': 'Atkin', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2022, 3, 23]]},
'reference': [ { 'key': '8794_CR1',
'unstructured': 'Coronavirus Update (Live): 46,432,714 Cases and 1,200,927 Deaths from '
'COVID-19 Virus Pandemic-Worldometer, '
'https://www.worldometers.info/coronavirus/.'},
{ 'key': '8794_CR2',
'doi-asserted-by': 'publisher',
'first-page': '221',
'DOI': '10.7326/m20-6169',
'volume': '174',
'author': 'DV Mehrotra',
'year': '2021',
'unstructured': 'Mehrotra, D. V. et al. Clinical endpoints for evaluating efficacy in '
'COVID-19 vaccine trials. Ann. Intern. Med. 174, 221–228. '
'https://doi.org/10.7326/m20-6169 (2021).',
'journal-title': 'Ann. Intern. Med.'},
{ 'key': '8794_CR3',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2007764',
'author': 'JH Beigel',
'year': '2020',
'unstructured': 'Beigel, J. H. et al. Remdesivir for the treatment of '
'Covid-19-preliminary report. N. Engl. J. Med. '
'https://doi.org/10.1056/NEJMoa2007764 (2020).',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': '8794_CR4',
'doi-asserted-by': 'publisher',
'first-page': '1488',
'DOI': '10.1016/j.ajem.2020.04.035',
'volume': '38',
'author': 'N Mehta',
'year': '2020',
'unstructured': 'Mehta, N., Mazer-Amirshahi, M., Alkindi, N. & Pourmand, A. '
'Pharmacotherapy in COVID-19; A narrative review for emergency providers. '
'Am. J. Emerg. Med. 38, 1488–1493. '
'https://doi.org/10.1016/j.ajem.2020.04.035 (2020).',
'journal-title': 'Am. J. Emerg. Med.'},
{ 'key': '8794_CR5',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijantimicag.2020.105949',
'volume': '56',
'author': 'P Gautret',
'year': '2020',
'unstructured': 'Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of '
'COVID-19: Results of an open-label non-randomized clinical trial. Int. '
'J. Antimicrob. Agents 56, 105949. '
'https://doi.org/10.1016/j.ijantimicag.2020.105949 (2020).',
'journal-title': 'Int. J. Antimicrob. Agents'},
{ 'key': '8794_CR6',
'doi-asserted-by': 'publisher',
'first-page': '2411',
'DOI': '10.1056/NEJMoa2012410',
'volume': '382',
'author': 'J Geleris',
'year': '2020',
'unstructured': 'Geleris, J. et al. Observational study of hydroxychloroquine in '
'hospitalized patients with Covid-19. N. Engl. J. Med. 382, 2411–2418. '
'https://doi.org/10.1056/NEJMoa2012410 (2020).',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': '8794_CR7',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.m1849',
'volume': '369',
'author': 'W Tang',
'year': '2020',
'unstructured': 'Tang, W. et al. Hydroxychloroquine in patients with mainly mild to '
'moderate coronavirus disease 2019: Open label, randomised controlled '
'trial. BMJ 369, m1849. https://doi.org/10.1136/bmj.m1849 (2020).',
'journal-title': 'BMJ'},
{ 'key': '8794_CR8',
'doi-asserted-by': 'publisher',
'first-page': '417',
'DOI': '10.1056/NEJMoa2021801',
'volume': '384',
'author': 'O Mitjà',
'year': '2021',
'unstructured': 'Mitjà, O. et al. A cluster-randomized trial of hydroxychloroquine for '
'prevention of Covid-19. N. Engl. J. Med. 384, 417–427. '
'https://doi.org/10.1056/NEJMoa2021801 (2021).',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': '8794_CR9',
'doi-asserted-by': 'publisher',
'first-page': '147',
'DOI': '10.1080/14787210.2020.1813024',
'volume': '19',
'author': 'D Echeverría-Esnal',
'year': '2021',
'unstructured': 'Echeverría-Esnal, D. et al. Azithromycin in the treatment of COVID-19: A '
'review. Expert Rev. Anti Infect. Ther. 19, 147–163. '
'https://doi.org/10.1080/14787210.2020.1813024 (2021).',
'journal-title': 'Expert Rev. Anti Infect. Ther.'},
{ 'key': '8794_CR10',
'doi-asserted-by': 'publisher',
'first-page': '9927',
'DOI': '10.1038/s41598-021-89444-5',
'volume': '11',
'author': 'M AlQahtani',
'year': '2021',
'unstructured': 'AlQahtani, M. et al. Randomized controlled trial of convalescent plasma '
'therapy against standard therapy in patients with severe COVID-19 '
'disease. Sci. Rep. 11, 9927. https://doi.org/10.1038/s41598-021-89444-5 '
'(2021).',
'journal-title': 'Sci. Rep.'},
{ 'key': '8794_CR11',
'doi-asserted-by': 'publisher',
'first-page': '167',
'DOI': '10.1007/s10238-020-00671-y',
'volume': '21',
'author': 'M Gavriatopoulou',
'year': '2021',
'unstructured': 'Gavriatopoulou, M. et al. Emerging treatment strategies for COVID-19 '
'infection. Clin. Exp. Med. 21, 167–179. '
'https://doi.org/10.1007/s10238-020-00671-y (2021).',
'journal-title': 'Clin. Exp. Med.'},
{ 'key': '8794_CR12',
'doi-asserted-by': 'publisher',
'first-page': '939',
'DOI': '10.1002/cbic.202000595',
'volume': '22',
'author': 'RO Sreekanth',
'year': '2021',
'unstructured': 'Sreekanth, R. O. & Lai, W.-F. Tackling COVID-19 using remdesivir and '
'favipiravir as therapeutic options. Chembiochem Eur. J. Chem. Biol. 22, '
'939–948. https://doi.org/10.1002/cbic.202000595 (2021).',
'journal-title': 'Chembiochem Eur. J. Chem. Biol.'},
{ 'key': '8794_CR13',
'doi-asserted-by': 'publisher',
'first-page': '85',
'DOI': '10.1016/j.antiviral.2018.03.003',
'volume': '153',
'author': 'L Delang',
'year': '2018',
'unstructured': 'Delang, L., Abdelnabi, R. & Neyts, J. Favipiravir as a potential '
'countermeasure against neglected and emerging RNA viruses. Antiviral '
'Res. 153, 85–94. https://doi.org/10.1016/j.antiviral.2018.03.003 (2018).',
'journal-title': 'Antiviral Res.'},
{ 'key': '8794_CR14',
'doi-asserted-by': 'publisher',
'first-page': '58',
'DOI': '10.5582/ddt.2020.01012',
'volume': '14',
'author': 'L Dong',
'year': '2020',
'unstructured': 'Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus '
'disease 2019 (COVID-19). Drug Discover. Therap. 14, 58–60. '
'https://doi.org/10.5582/ddt.2020.01012 (2020).',
'journal-title': 'Drug Discover. Therap.'},
{ 'key': '8794_CR15',
'doi-asserted-by': 'publisher',
'first-page': '1192',
'DOI': '10.1016/j.eng.2020.03.007',
'volume': '6',
'author': 'Q Cai',
'year': '2020',
'unstructured': 'Cai, Q. et al. Experimental treatment with favipiravir for COVID-19: An '
'open-label control study. Engineering (Beijing) 6, 1192–1198. '
'https://doi.org/10.1016/j.eng.2020.03.007 (2020).',
'journal-title': 'Engineering (Beijing)'},
{ 'key': '8794_CR16',
'doi-asserted-by': 'publisher',
'DOI': '10.2807/1560-7917.Es.2020.25.3.2000045',
'author': 'VM Corman',
'year': '2020',
'unstructured': 'Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by '
'real-time RT-PCR. Euro Surveill '
'https://doi.org/10.2807/1560-7917.Es.2020.25.3.2000045 (2020).',
'journal-title': 'Euro Surveill'},
{ 'key': '8794_CR17',
'doi-asserted-by': 'publisher',
'first-page': '1793',
'DOI': '10.1097/00003246-199811000-00016',
'volume': '26',
'author': 'JL Vincent',
'year': '1998',
'unstructured': 'Vincent, J. L. et al. Use of the SOFA score to assess the incidence of '
'organ dysfunction/failure in intensive care units: Results of a '
'multicenter, prospective study. Working group on “sepsis-related '
'problems” of the European Society of Intensive Care Medicine. Crit. Care '
'Med. 26, 1793–1800. https://doi.org/10.1097/00003246-199811000-00016 '
'(1998).',
'journal-title': 'Crit. Care Med.'},
{ 'key': '8794_CR18',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.intimp.2020.107301',
'volume': '91',
'author': 'M Shah',
'year': '2021',
'unstructured': 'Shah, M. et al. Safety and efficacy of ozone therapy in mild to moderate '
'COVID-19 patients: A phase 1/11 randomized control trial (SEOT study). '
'Int. Immunopharmacol. 91, 107301. '
'https://doi.org/10.1016/j.intimp.2020.107301 (2021).',
'journal-title': 'Int. Immunopharmacol.'},
{ 'key': '8794_CR19',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.tmaid.2020.101663',
'volume': '34',
'author': 'P Gautret',
'year': '2020',
'unstructured': 'Gautret, P. et al. Clinical and microbiological effect of a combination '
'of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at '
'least a six-day follow up: A pilot observational study. Travel Med. '
'Infect. Dis. 34, 101663. https://doi.org/10.1016/j.tmaid.2020.101663 '
'(2020).',
'journal-title': 'Travel Med. Infect. Dis.'},
{ 'key': '8794_CR20',
'doi-asserted-by': 'publisher',
'first-page': '2455',
'DOI': '10.1002/sim.4780132309',
'volume': '13',
'author': 'MA Birkett',
'year': '1994',
'unstructured': 'Birkett, M. A. & Day, S. J. Internal pilot studies for estimating sample '
'size. Stat. Med. 13, 2455–2463 (1994).',
'journal-title': 'Stat. Med.'},
{ 'key': '8794_CR21',
'doi-asserted-by': 'publisher',
'first-page': '62',
'DOI': '10.1016/j.ijid.2020.11.142',
'volume': '103',
'author': 'ZF Udwadia',
'year': '2021',
'unstructured': 'Udwadia, Z. F. et al. Efficacy and safety of favipiravir, an oral '
'RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A '
'randomized, comparative, open-label, multicenter, phase 3 clinical '
'trial. Int. J. Infect. Dis. 103, 62–71 (2021).',
'journal-title': 'Int. J. Infect. Dis.'},
{ 'key': '8794_CR22',
'doi-asserted-by': 'publisher',
'first-page': '1',
'DOI': '10.1038/s41598-021-90551-6',
'volume': '11',
'author': 'S Hassanipour',
'year': '2021',
'unstructured': 'Hassanipour, S. et al. The efficacy and safety of Favipiravir in '
'treatment of COVID-19: A systematic review and meta-analysis of clinical '
'trials. Sci. Rep. 11, 1–11 (2021).',
'journal-title': 'Sci. Rep.'},
{ 'key': '8794_CR23',
'doi-asserted-by': 'publisher',
'DOI': '10.1183/13993003.01157-2020',
'author': 'M Vicenzi',
'year': '2020',
'unstructured': 'Vicenzi, M. et al. The liaison between respiratory failure and high '
'blood pressure: Evidence from COVID-19 patients. Eur. Respir. J. '
'https://doi.org/10.1183/13993003.01157-2020 (2020).',
'journal-title': 'Eur. Respir. J.'},
{ 'issue': '2',
'key': '8794_CR24',
'doi-asserted-by': 'publisher',
'first-page': '65',
'DOI': '10.1590/1806-9282.66.S2.65',
'volume': '66',
'author': 'S Yaylaci',
'year': '2020',
'unstructured': 'Yaylaci, S. et al. The effects of favipiravir on hematological '
'parameters of covıd-19 patients. Rev. Assoc Med. Bras (1992) 66(2), '
'65–70. https://doi.org/10.1590/1806-9282.66.S2.65 (2020).',
'journal-title': 'Rev. Assoc Med. Bras (1992)'},
{ 'key': '8794_CR25',
'doi-asserted-by': 'publisher',
'first-page': '87',
'DOI': '10.1620/tjem.251.87',
'volume': '251',
'author': 'E Mishima',
'year': '2020',
'unstructured': 'Mishima, E., Anzai, N., Miyazaki, M. & Abe, T. Uric acid elevation by '
'favipiravir, an antiviral drug. Tohoku J. Exp. Med. 251, 87–90. '
'https://doi.org/10.1620/tjem.251.87 (2020).',
'journal-title': 'Tohoku J. Exp. Med.'},
{ 'key': '8794_CR26',
'doi-asserted-by': 'publisher',
'first-page': '430',
'DOI': '10.1016/j.resinv.2020.08.001',
'volume': '58',
'author': 'K Murohashi',
'year': '2020',
'unstructured': 'Murohashi, K. et al. Outcome of early-stage combination treatment with '
'favipiravir and methylprednisolone for severe COVID-19 pneumonia: A '
'report of 11 cases. Respir. Investig. 58, 430–434. '
'https://doi.org/10.1016/j.resinv.2020.08.001 (2020).',
'journal-title': 'Respir. Investig.'},
{ 'key': '8794_CR27',
'doi-asserted-by': 'publisher',
'first-page': '732',
'DOI': '10.1093/cid/ciaa237',
'volume': '71',
'author': 'X Yao',
'year': '2020',
'unstructured': 'Yao, X. et al. In Vitro antiviral activity and projection of optimized '
'dosing design of hydroxychloroquine for the treatment of severe acute '
'respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, '
'732–739. https://doi.org/10.1093/cid/ciaa237 (2020).',
'journal-title': 'Clin. Infect. Dis.'},
{ 'key': '8794_CR28',
'doi-asserted-by': 'publisher',
'first-page': '2411',
'DOI': '10.1056/NEJMoa2012410',
'volume': '382',
'author': 'J Geleris',
'year': '2020',
'unstructured': 'Geleris, J. et al. Observational study of hydroxychloroquine in '
'hospitalized patients with Covid-19. N. Engl. J. Med. 382, 2411–2418 '
'(2020).',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': '8794_CR29',
'doi-asserted-by': 'publisher',
'first-page': '1',
'DOI': '10.1038/s41598-020-77748-x',
'volume': '10',
'author': 'RM Ghazy',
'year': '2020',
'unstructured': 'Ghazy, R. M. et al. A systematic review and meta-analysis on chloroquine '
'and hydroxychloroquine as monotherapy or combined with azithromycin in '
'COVID-19 treatment. Sci. Rep. 10, 1–18 (2020).',
'journal-title': 'Sci. Rep.'},
{ 'key': '8794_CR30',
'doi-asserted-by': 'publisher',
'first-page': '573',
'DOI': '10.1007/s40121-020-00324-3',
'volume': '9',
'author': 'SN Rao',
'year': '2020',
'unstructured': 'Rao, S. N., Manissero, D., Steele, V. R. & Pareja, J. A systematic '
'review of the clinical utility of cycle threshold values in the context '
'of COVID-19. Infect. Dis. Ther. 9, 573–586. '
'https://doi.org/10.1007/s40121-020-00324-3 (2020).',
'journal-title': 'Infect. Dis. Ther.'},
{ 'key': '8794_CR31',
'doi-asserted-by': 'publisher',
'first-page': '1008',
'DOI': '10.1073/pnas.2017962118',
'volume': '118',
'author': 'N Néant',
'year': '2021',
'unstructured': 'Néant, N. et al. (2021) Modeling SARS-CoV-2 viral kinetics and '
'association with mortality in hospitalized patients from the French '
'COVID cohort. Proc. Natl. Acad. Sci. USA 118, 1008. '
'https://doi.org/10.1073/pnas.2017962118 (2021).',
'journal-title': 'Proc. Natl. Acad. Sci. USA'}],
'container-title': 'Scientific Reports',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-08794-w.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-022-08794-w',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-022-08794-w.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 11, 25]],
'date-time': '2022-11-25T01:03:03Z',
'timestamp': 1669338183000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-08794-w'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3, 23]]},
'references-count': 31,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}},
'alternative-id': ['8794'],
'URL': 'http://dx.doi.org/10.1038/s41598-022-08794-w',
'relation': {},
'ISSN': ['2045-2322'],
'subject': ['Multidisciplinary'],
'container-title-short': 'Sci Rep',
'published': {'date-parts': [[2022, 3, 23]]},
'assertion': [ { 'value': '12 July 2021',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '7 February 2022',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '23 March 2022',
'order': 3,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '26 September 2022',
'order': 4,
'name': 'change_date',
'label': 'Change Date',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'Correction',
'order': 5,
'name': 'change_type',
'label': 'Change Type',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'A Correction to this paper has been published:',
'order': 6,
'name': 'change_details',
'label': 'Change Details',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'https://doi.org/10.1038/s41598-022-20899-w',
'URL': 'https://doi.org/10.1038/s41598-022-20899-w',
'order': 7,
'name': 'change_details',
'label': 'Change Details',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'The authors declare no competing interests.',
'order': 1,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}],
'article-number': '4925'}
